Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The following criteria must have been met at the initial start of aflibercept treatment (i.e. start of aflibercept treatment at least 1 year before this study):~  * Subject had primary subfoveal choroidal neovascularization (CNV) lesions secondary to nAMD, including juxtafoveal lesions that affect the fovea, as evidenced by fluorescein angiography/photography (FA/FP) of the study eye within 3 weeks before the initiation of aflibercept treatment.~ * The area of CNV occupied at least 50% of the total lesion within 3 weeks before the initiation of aflibercept treatment.~ * Documented best-corrected visual acuity (BCVA) was 20/40 to 20/320 (letter score of 73 to 25) in the study eye at the initiation of treatment.~* Men and women \>= 51 years of age~* The subject's history of aflibercept treatment meets ALL of the following:~  * Treatment in the study eye was initiated with three monthly (-1 week/+2 weeks) doses of 2 mg aflibercept and improvements of visual and anatomic outcomes were observed~ * Following the above initiation phase, the intervals between treatments were between 6 weeks and 12 weeks~Exclusion Criteria:~- Any prior or concomitant therapy with an investigational or approved agent to treat neovascular AMD in the study eye other than aflibercept.~* Total lesion size \> 12 disc areas (30.5 mm2, including blood, scars and neovascularization) as assessed by fluorescein angiography (FA) in the study eye~* Subretinal hemorrhage that was:~  1. 50% or more of the total lesion area, or~ 2. if the blood was under the fovea, and~ 3. the blood under the fovea was 1 or more disc areas in size in the study eye.~* Scar or fibrosis making up more than 50% of the total lesion in the study eye.~* Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.~* Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.~* Causes of CNV other than AMD in the study eye.

- Gender: ALL
- Minimum Age: 51 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept extended dosing (Type: EXPERIMENTAL): Aflibercept was administered 2mg per injection intravitreal (IVT) in the study eye in Aflibercept extended dosing. Flexible dosing interval is ≥ 8 weeks (no upper limit) based on visual and anatomic outcomes as judged by the investigator. When/if visual and anatomical outcomes indicated that the disease had re-activated, the treatment interval reverted to the last treatment interval in which the disease was inactive (ie, no signs of exudation were observed).
- Aflibercept 2Q8 (2 mg aflibercept administered every 8 weeks) (Type: ACTIVE_COMPARATOR): Aflibercept was administered 2mg per injection IVT in the study eye in Aflibercept 2Q8. Fixed dosing interval is 8 weeks (±3 days), modification of the treatment interval was not allowed.

Based on this trial design, predict the completion outcome and termination type (if applicable).